UK MHRA proposes safeguard for medicines supplies for patients

1 November 2011

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has proposed repeal of the part of the Medicines Act which permits trading between pharmacies without the need for a wholesalers licence.

The Medicines Act 1968 contains an exemption which allows pharmacies in the UK to trade pharmaceutical products without the requirement to hold a wholesale dealers' licence. This law is incompatible with more recent European Union legislation and trading in future will need to be only where it meets the needs of public health, is in small quantities, is infrequent, and is not for profit.

There is a great deal of trading between pharmacies at present, particularly within the National Health Service, and the MHRA says it would not wish to impose the full licensing arrangements upon a public service, as this would be disproportionate. Government intervention is necessary for the repeal of Section 10(7), but also to provide a regime under which essential supplies of medicines continue to reach patients in need.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical